Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a clinical-stage, precision medicine pharmaceutical company with a novel Drug Response Predictor (DRP) platform that aims to improve patient selection for their lead program Stenoparib, currently in Phase 2 trials for ovarian and small cell lung cancer. Stenoparib has shown promising results in trials, with some patients still receiving benefits after 29 months on therapy and a median overall survival of 25 months. With a large market potential for ovarian cancer and the growing PARP inhibitors market, coupled with a positive balance sheet and recent Q3 results, Allarity presents as a high-risk, high-reward opportunity for investors.

Bears say

Allarity Therapeutics is currently trading at an attractive valuation, with a BUY rating and a raised 12-month price target of $9.75 based on a NPV analysis. While there are risks involved, such as balance sheet and liquidity risks, the company's innovative DRP platform and its main drug candidate, Stenoparib, show potential for personalized and precision medicine in the treatment of ovarian cancer, with recent data showing promising results and a large market potential. The company has a strong balance sheet, with enough cash to support its operations until at least late 2026.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.